Cutting-edge computer software helps pinpoint aggressiveness of breast cancer tumors — ScienceDaily
Their findings are published today in the journal, Nature Scientific Reports. …
Their findings are published today in the journal, Nature Scientific Reports. …
Their findings are published today in the journal, Nature Scientific Reports. “We are using a unique software program in our lab that looks at a type of mutation called a splicing mutation that is typically overlooked using current methods,” said lead author on the study, Stephanie Dorman, a PhD student in the department of biochemistry at Western University’s Schulich School of Medicine & Dentistry. She said that where previous genetic studies of 445 tumours detected 429 of these splicing mutations, the Western-developed analysis software was able to find more than 5000. Using this software and human tumour tissue sample genetic data from The Cancer Genome Atlas, the research team pinpointed that mutations in the Neural Cell Adhesion Molecule (NCAM) and other related genes in NCAM biology were present at a much higher rate in tumours which had metastasized to the lymph nodes than those that did not…
A novel medical-imaging technology, TexRAD, which analyses the texture of tumors, has been shown in trials to enable early diagnosis of those bowel-cancer patients not responding to the standard cancer therapy better than other available tumor markers. Furthermore, the TexRAD markers showed the ability to assess at an early stage the likelihood of survival, distinguishing patients who will have a good prognosis from those having poor prognosis. Dr Balaji Ganeshan, one of the Sussex academics whose research led to the development of the technology, said: “By using TexRAD to scan for subtle anomalies in a tumor’s texture, researchers have been able to spot more quickly when treatments are — or are not — working and adjust treatment accordingly. “And because TexRAD simply provides an additional layer of software analysis of the MRI and CT scans that already exist as part of routine clinical practice, it is non-invasive from the patient’s point of view and potentially cost-effective to the healthcare provider.” The technology is being evaluated in a number of research institutions and university hospitals around the world. …
That results in lots of needless worry for women and their families — not to mention the time, discomfort and expense of additional tests, including ultrasounds and biopsies. Recently, a different type of test, ultrasound elastography, has been used to pinpoint possible tumors throughout the body, including in the breast. “It uses imaging to measure the stiffness of tissue, and cancer tissues are stiff,” says Jingfeng Jiang, a biomedical engineer at Michigan Technological University…
That results in lots of needless worry for women and their families — not to mention the time, discomfort and expense of additional tests, including ultrasounds and biopsies. Recently, a different type of test, ultrasound elastography, has been used to pinpoint possible tumors throughout the body, including in the breast. “It uses imaging to measure the stiffness of tissue, and cancer tissues are stiff,” says Jingfeng Jiang, a biomedical engineer at Michigan Technological University. Those images can be breathtakingly clear: Jiang shows one elastogram in which the tumor is as different from normal breast tissue as a yolk is from the white in a fried egg. …
Tumor removal surgeries pose a great challenge even to skillful and experienced surgeons. …
After more than a decade of work, UC Irvine chemists have created a way to clearly identify clinically usable markers for prostate cancer in urine, meaning that the disease could be detected far sooner, with greater accuracy and at dramatically lower cost. The same technology could potentially be used for bladder and multiple myeloma cancers, which also shed identifiable markers in urine. "Our goal is a device the size of a home pregnancy test priced around $10…